SANDOZ

CABAZITAXEL (SANDOZ)

Manufacturer:

SANDOZ

Cabazitaxel (Sandoz) HCPCS:

J9064

HCPCS Code Descriptor:

Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg

Category:

J Code

Cabazitaxel (Sandoz) NDCs:

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Cabazitaxel (Sandoz):

Cabazitaxel (Sandoz) is an oncology drug manufactured by Sandoz and administered via the Intravenous route of administration. The J Code: J9064 is aligned to the drug Cabazitaxel (Sandoz).

ACCESS PRICING AND MORE BY REGISTERING

J9064 Added Date:

October 1, 2023

J9064 Effective Date:

October 1, 2023

J9064 Termination Date:

We have not yet identified a manufacturer source of Cabazitaxel (Sandoz) billing and coding information.
CABAZITAXEL (SANDOZ) prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for CABAZITAXEL (SANDOZ). Please check back in a few weeks.